Starting this week with Novartis AG, Johnson & Johnson and Roche followed next week by Eli Lilly & Co., GlaxoSmithKline PLC, Bayer AG , AstraZeneca PLC, Sanofi and Merck & Co. Inc. , the pharmaceutical majors will roll out their big wheels to tell investors how things have been going in the first half of the year and how forecasts of just six months ago need to be tweaked in the light of reality.
Results seasons traditionally are turbulent: it is not a coincidence that when CEOs open their mouths to express naked financial...
Welcome to Scrip
Create an account to read this article
Already a subscriber?